3 / 9
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
Vaccines & Vaccination and Gynecologic Oncology 2018
Page 19
Biography
S Parida is trained as a Veterinarian and has completed his
PhD in 1998 from TANUVAS, India and Postdoctoral studies
from Institute for Animal Health, UK through Welcome Trust
Travelling Research Fellowship. He is the Head of the Vaccine
Differentiation group at the Pirbright Institute at UK since 2007
and additionally, he is a Jenner Investigator at the Oxford
University and a Visiting Professor at Royal Veterinary College,
UK. He has published more than 129 papers in reputed journals
and has been serving as an Editorial Board Member of
PLOS
One and Transboundary Emerging Diseases
.
satya.parida@pirbright.ac.ukImproving the duration of immunity for
FMD vaccines
S Parida
1
, K Lloyd-Jones
1
, R Herbert
1
,
K Parekh
1
, M Madhanmohan
2
, S B
Nagendrakumar
2
, A Milicic
3
and V A
Srinivasan
2
1
The Pirbright Institute, UK
2
Indian Immunologicals Limited, India
3
Jenner Institute, University of Oxford, UK
S Parida et al., Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-004
C
hemically inactivated, oil adjuvanted foot and mouth disease (FMD) vaccines
are a critical element in FMD control in developing countries. Although these
vaccines are effective in pigs and ruminants, protective immunity is not reached
quickly, is short-lived (~3 months) and is serotype and sometimes strain-specific.
More appropriate vaccine strains that induce broader protection, together with
identification of novel adjuvants that provide a greater duration of immunity
and simplified methods to measure vaccine quality would make a significant
contribution to FMD control and to livestock development in developing countries.
Oil adjuvant vaccines induce variable T cell responses, whilst novel adjuvants can
prime greater and more consistent T cell and humoral responses that may give
longer duration of protection. In our CIDLID funded grant, we had selected eight
new adjuvants as potent immune enhancers, including ligands for TLR receptors
that enhanced Th1 priming in various human or animal vaccines. The aim was
to supplement the oil component of the adjuvant with a novel immunostimulant
that impacts on TLR or related signaling pathways. These eight new adjuvanted
vaccines were tested in a pilot study in cattle at IIL, India. The four most efficacious
ones (MPLA, Poly I: C, Abisco 300 and R848) were retested for Serotype A in a
larger number of cattle at Pirbright, UK. The vaccinated cattle were challenged
on 21 days post-vaccination. The most efficacious adjuvant, poly I: C, tested
further in cattle for serotype O FMD vaccine for 7.5 months to assess its impact
on the duration of immunity. The enhanced humoral and cellular responses were
observed by incorporating poly I: C in FMD vaccine that increased the duration
of immunity in comparison to the conventional oil adjuvant vaccine. Therefore,
we conclude that there is a measurable T cell component to vaccine-induced
protection in addition to humoral antibody component and strengthening this
would improve efficacy and duration of immunity.
Euro Vaccines 2018